NLRP3 and atherosclerosis: MYPT‐1 phosphorylation is a marker of ROCK activity and plays a crucial role in cardiovascular‐renal remodelling.59 As a NADPH rate‐controlling enzyme, HMGCR is a target for atherosclerosis‐ameliorative drug because it participates in cholesterol synthesis.60 Moreover, NLRP3 inflammasome was reported to be involved in the pathological progression of multiple CVDs such as myocardial ischaemia disorders, atherosclerosis, hypertension and cardiomyopathy.61 Therefore, natural compounds targeting markers above can be regarded as potential candidates to ameliorate CVDs.